Cantor Fitzgerald Boosts Amicus Therapeutics (NASDAQ:FOLD) Price Target to $21.00

Amicus Therapeutics (NASDAQ:FOLD) had its price target boosted by equities researchers at Cantor Fitzgerald from $20.00 to $21.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has an “overweight” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective suggests a potential upside of 91.08% from the company’s previous close.

Several other analysts have also recently issued reports on FOLD. Bank of America increased their target price on Amicus Therapeutics from $13.00 to $15.00 and gave the stock a “buy” rating in a research report on Thursday, October 17th. StockNews.com cut shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Needham & Company LLC restated a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday. Morgan Stanley reduced their price target on shares of Amicus Therapeutics from $19.00 to $18.00 and set an “overweight” rating on the stock in a report on Friday, October 11th. Finally, Jefferies Financial Group initiated coverage on Amicus Therapeutics in a research report on Friday, September 6th. They set a “buy” rating and a $18.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $17.50.

Amicus Therapeutics Stock Performance

Shares of NASDAQ:FOLD traded up $0.01 during trading on Thursday, hitting $10.99. The company’s stock had a trading volume of 2,096,772 shares, compared to its average volume of 2,700,833. The company has a debt-to-equity ratio of 2.93, a current ratio of 2.75 and a quick ratio of 2.26. The company has a 50-day moving average of $11.13 and a 200-day moving average of $10.61. Amicus Therapeutics has a 12 month low of $9.02 and a 12 month high of $14.57.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) EPS for the quarter, hitting analysts’ consensus estimates of ($0.05). The company had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative return on equity of 17.03% and a negative net margin of 21.21%. Amicus Therapeutics’s revenue for the quarter was up 34.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.15) EPS. On average, sell-side analysts anticipate that Amicus Therapeutics will post -0.06 earnings per share for the current year.

Insider Buying and Selling at Amicus Therapeutics

In related news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,398,532.40. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In other news, CEO Bradley L. Campbell sold 7,500 shares of the company’s stock in a transaction that occurred on Tuesday, October 1st. The stock was sold at an average price of $10.60, for a total transaction of $79,500.00. Following the transaction, the chief executive officer now owns 886,654 shares of the company’s stock, valued at approximately $9,398,532.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Bradley L. Campbell sold 7,901 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $12.50, for a total value of $98,762.50. Following the completion of the sale, the chief executive officer now owns 886,654 shares in the company, valued at approximately $11,083,175. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,401 shares of company stock worth $352,038 over the last quarter. Insiders own 2.20% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. OLD Second National Bank of Aurora purchased a new position in shares of Amicus Therapeutics during the third quarter worth approximately $26,000. Hazlett Burt & Watson Inc. grew its position in shares of Amicus Therapeutics by 156.9% during the 3rd quarter. Hazlett Burt & Watson Inc. now owns 2,569 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 1,569 shares in the last quarter. Blue Trust Inc. increased its stake in shares of Amicus Therapeutics by 1,705.4% during the third quarter. Blue Trust Inc. now owns 2,997 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 2,831 shares during the period. Arcadia Investment Management Corp MI bought a new stake in shares of Amicus Therapeutics in the third quarter valued at about $32,000. Finally, Headlands Technologies LLC purchased a new stake in Amicus Therapeutics in the second quarter worth about $89,000.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.